QAP 1: A New Drug That Inhibits Topoisomerase II in Cancer Cells
Author Information
Author(s): Patrick Chène, Joëlle Rudloff, Joseph Schoepfer, Pascal Furet, Peter Meier, Zhiyan Qian, Jean-Marc Schlaeppi, Rita Schmitz, Thomas Radimerski
Primary Institution: Novartis Institutes for BioMedical Research, Basel, Switzerland
Hypothesis
Can a novel purine analogue effectively inhibit topoisomerase II and show increased sensitivity in BRCA1 mutant breast cancer cells?
Conclusion
QAP 1 is a potent ATP-competitive inhibitor of topoisomerase II that shows promise as an anti-cancer therapy, particularly for BRCA1 mutant tumors.
Supporting Evidence
- QAP 1 inhibited topoisomerase II ATPase activity and decatenation at sub-micromolar concentrations.
- BRCA1 mutant breast cancer cells showed increased sensitivity to QAP 1 compared to reconstituted BRCA1 cells.
- QAP 1 displayed selectivity over a panel of kinases, indicating potential for reduced side effects.
Takeaway
Scientists created a new drug called QAP 1 that stops a protein important for cancer cells from working, especially in certain types of breast cancer cells.
Methodology
The study involved screening a compound library for ATP-competitive inhibitors of topoisomerase II using enzymatic assays and cell-based assays.
Potential Biases
Potential bias in the selection of compounds and the interpretation of results based on the authors' affiliations with Novartis.
Limitations
The study does not address the long-term effects of QAP 1 on normal cells or the potential for resistance development.
Participant Demographics
The study primarily focused on BRCA1 mutant breast cancer cell lines and HL-60 leukemic cells.
Statistical Information
P-Value
p ≤ 0.05
Statistical Significance
p ≤ 0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website